Psychiatry7 Sept 2026
Beyond diabetes: Semaglutide's surprising signal in bipolar disorderRead article
Endocrinology19 Sept 2026
Sex and hypoglycaemia in type 1 diabetes: what CGM data now showRead article
Lung cancer in never smokers: The 60x risk factor you might be missing
A specific EGFR variant significantly increases lung cancer risk in individuals who have never smoked, challenging traditional views on lung cancer etiology. This genetic predisposition highlights a critical, often overlooked, pathway to disease development.
PD-L1 isn't just a biomarker for HNSCC, it's a treatment guide
PD-L1 expression guides immunotherapy selection in recurrent and metastatic head and neck squamous cell carcinoma, with varying efficacy across patient subgroups.
Breast cancer home injections: Convenient for patients, complex for insurers
Despite the clinical benefits of home-based breast cancer therapy, insurance policies frequently impede patient access to these convenient injection programs.
Low-risk thyroid cancer: Time to rethink radioactive iodine?
Ovarian cancer: Early detection isn't the answer we thought
HPV-positive OPSCC: Are we overtreating excellent prognoses?
Multicancer early detection: Can we screen for what we can't treat?
PPIs and cancer: Is CYP2C19 a friend or foe?
Salivary gland cancer: Is HER2-low the new HER2-positive?
Routine childhood vaccines: Less coverage means more than just infections
Routine childhood vaccination coverage has stagnated globally, with persistent inequities amplified by the COVID-19 pandemic, raising concerns for future health outcomes.
Noninvasive Ventilation: A Shift in End-of-Life Care for ALS?
Noninvasive ventilation may reduce requests for medical assistance in dying (MAiD) among patients with amyotrophic lateral sclerosis (ALS). This suggests a potential impact on end-of-life decisions.
Dual-target gene therapy: Can it free Parkinson's patients from levodopa dependence?
A dual-target gene therapy, BBM-P002, demonstrated a favorable safety profile in a Phase 1 trial for moderate-to-advanced Parkinson's disease.
Brexpiprazole for Alzheimer's agitation: Antidepressants don't change efficacy
Fibromyalgia: Is the pain real if the tissue damage isn't?
Can mice learn to control their own brains? A new neurofeedback system
Bilateral Focused Ultrasound: A New Path for Parkinson's Motor Control?
Alzheimer's blood tests: Why are unverified claims spreading so fast?
Hyperactivity and ID: It's not just genetics, it's O-GlcNAc dyshomeostasis
LeukemiaRusfertide and hepcidin mimetics: a different way to control erythrocytosis
Get the full storyHaematocrit targets: Is 45% still the right threshold for phlebotomy?
Get the full storyWhy molecular response in polycythemia vera remains an elusive endpoint
Get the full storyPNH: Beyond Eculizumab, How Proximal Inhibition Reshaped Treatment Goals
Get the full storyWhen complement inhibitors fail: Recognizing breakthrough haemolysis
Get the full storyOral factor B inhibition: a new path for PNH management?
Get the full storyMyelofibrosis: Why transplant timing dictates survival, not just symptoms
Get the full storyChoosing a JAK Inhibitor in Myelofibrosis: Beyond Ruxolitinib
Get the full storyMomelotinib and anaemia in myelofibrosis: a new calculus for treatment?
Get the full storyGene therapy for thalassemia: Approval is one hurdle, access is the next
Get the full storySjögren's Disease: Early Damage Often Present at Diagnosis
Get the full storySjögren's Disease: Bridging the 5-Year Diagnostic Gap to Emerging Therapies
Get the full storyCrystal Arthritis: The ICU Fever You Keep Missing
Get the full storyWhen Joint Pain Strikes: Distinguishing Gout, Pseudogout, and Septic Arthritis
Get the full storyCalcium Pyrophosphate Deposition Disease: What the 2023 Criteria Enable
Get the full storyAntiphospholipid Antibody Testing: When to Trust the Results
Get the full storyWhy triple-positive antiphospholipid syndrome defies direct oral anticoagulants
Get the full storyStatin-associated myopathy: rare, real, and reversible?
Get the full storyMyositis-Specific Autoantibodies: Predicting Prognosis and Guiding Screening
Get the full storyAutologous Stem Cell Transplant in Scleroderma: Who Justifies the Risk?
Get the full story
Idiopathic Pulmonary FibrosisIPF: Why new therapies are still missing the mark
Get the full storyAlpha-1 Antitrypsin Deficiency: Why fragmented care costs lives
Get the full storyRespiratory care: Why neurology's long-acting therapies could be key
Get the full storyRethink PDE inhibition in COPD: Not all isoforms are equal
Get the full storySevere asthma: Why targeted therapies miss some Type 2 patients
Get the full storyPH-ILD: Why current vasodilators fall short, and what's next
Get the full storyBeyond rescue inhalers: What really keeps COPD patients out of hospital?
Get the full storyCOPD exercise limits: Is your oxygen therapy doing enough?
Get the full storyChronic lung disease: Why early diagnosis still isn't enough
Get the full storySleep Apnea: Why AHI Misses What Matters Most
Get the full story
Clostridioides difficileRSV and COVID-19 vaccines: Why are we still underestimating their impact?
Get the full storyBixlenvo: Is the smallest HIV pill also the biggest advantage?
Get the full storyDolutegravir for HIV in newborns: A new option for an urgent need
Get the full storyUndiagnosed TB deaths in England highlight diagnostic failures
Get the full storySerology and PCR: Optimising COVID-19 Episode Identification
Get the full storyAsymptomatic bacteriuria: The treatment decision that fuels antibiotic resistance
Get the full storyWhy syphilis rates keep climbing in high-income countries
Get the full storyCongenital Syphilis: The Missed Opportunities Behind Rising Case Counts
Get the full storyDoxycycline PEP: When it works for STIs, and when it doesn't
Get the full storyClade I outbreak: Where did the vaccine supply go?
Get the full story
Dermatitis AtopicDermatomyositis: Why an oral JAK inhibitor changes everything
Get the full storyCould immune system modulation be the next frontier in skincare?
Get the full storyWhy rosacea flushing resists standard therapy: a neurovascular disconnect
Get the full storyMatching rosacea therapy to dominant features: A phenotype-led approach
Get the full storyDoes targeting Demodex mites improve rosacea outcomes?
Get the full storyAntihistamine-refractory urticaria: when standard care falls short
Get the full storyChronic Urticaria: The Diagnostic Tests That Rarely Help
Get the full storyRemibrutinib: A New BTK Inhibitor for Chronic Urticaria Beyond Omalizumab
Get the full storyAlopecia Areata: What happens when patients stop treatment?
Get the full storyJAK Inhibitors for Alopecia: What Monitoring Do Patients Actually Need?
Get the full storyAn epidemiological shift in T2D is reshaping drug development and market access for oncology and metabolic portfolios.
The most resistant cancer is finally responding, and the pipeline is accelerating
Lecanemab and donanemab are approved. The harder question is who gets them and how
Label expansion triples the eligible population and the infrastructure race begins
From 1 approval to 15: how the ADC platform reshaped every solid tumor type
ACLF: Why G-CSF works for some, but fails others
Specific immune cell populations and inflammatory markers predict G-CSF treatment response and mortality in acute-on-chronic liver failure, a GRAFT sub-study shows.
Why primary sclerosing cholangitis remains a therapeutic graveyard
Despite numerous attempts, no disease-modifying therapy has succeeded in primary sclerosing cholangitis, leaving transplant as the only definitive treatment.
MASH: Why diabetes management now demands a liver-first approach?
Emerging liver-directed approaches for moderate to advanced MASH are reshaping treatment paradigms, with significant implications for diabetes specialists managing metabolic dysfunction.
Seladelpar and Elafibranor: The Second-Line Options for PBC After Ursodeoxycholic Acid Fails
Chronic hepatitis B: Is PD-1 blockade the key to T-cell revival?
Seladelpar and elafibranor: second-line options for PBC
Eplontersen for ATTR-CM: Why a promising therapy fell short
Eplontersen, when added to standard care, did not demonstrate additional cardiovascular benefit for patients with ATTR-CM. The therapy's impact on cardiac outcomes remains unconfirmed.
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Electrocardiogram waveforms offer insights into myocardial infarction with epicardial coronary artery disease (MI-E) efficacy, providing a non-invasive window into myocardial health.
DOACs for AFib: Are intermediate-risk patients getting the protection they need?
Direct oral anticoagulants (DOACs) reduce clinical events in atrial fibrillation patients at intermediate stroke risk, challenging prior assumptions about optimal management in this group.
Early type 2 diabetes: Is remission the new normal for young adults?
A low-energy diet paired with structured exercise achieved diabetes remission in 54% of adults with early-onset type 2 diabetes, versus 4% with usual care.
Low-carb diets in kids with type 1 diabetes: safe, but not standard?
In 45,569 children, very low carbohydrate diets were not linked to poorer growth, severe hypoglycaemia or ketoacidosis, though the evidence remains observational.
Rotavirus vaccine and T1D: Is an 11% rise cause for alarm?
Type 1 diabetes incidence in Norwegian children rose 11% after rotavirus vaccination began, but similar rises followed unrelated vaccine changes.
Pruritus in primary biliary cholangitis: the symptom that drives quality of life
AdvertisementAdvertisementAdvertisement
• Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US 
• Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12UEG Week 2026 • Barcelona, ES • Oct 17 – 20Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27ACR 2026 • Orlando, US • Nov 6 – 11AHA 2026 • Chicago, US • Nov 6 – 9ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12
Advertisement
BarcelonaSep 5 – 9 2026
Alpha-1 Antitrypsin Deficiency: Why fragmented care costs lives
Alpha-1 antitrypsin deficiency presents as both a respiratory and hepatic disease, often leading to diagnostic delays and suboptimal management due to fragmented care.
Severe asthma: Why targeted therapies miss some Type 2 patients
Emerging clinical insights suggest the distal airways play a more central role in Type 2 severe asthma pathophysiology than previously understood.
PH-ILD: Why current vasodilators fall short, and what's next
An inhaled sGC activator is under investigation for pulmonary hypertension associated with interstitial lung disease, a condition with significant unmet need.
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Electrocardiogram waveforms offer insights into myocardial infarction with epicardial coronary artery disease (MI-E) efficacy, providing a non-invasive window into myocardial health.
Rethink PDE inhibition in COPD: Not all isoforms are equal
Phosphodiesterase (PDE) inhibitors offer therapeutic potential in COPD, but adverse effects, particularly nausea with PDE4 inhibitors and cardiovascular risks with chronic PDE3 inhibition, limit their broader application.
IPF: Why new therapies are still missing the mark
The TETON Phase 3 clinical program provides new insights into the management of idiopathic pulmonary fibrosis, highlighting both progress and persistent challenges.
RSV and COVID-19 vaccines: Why are we still underestimating their impact?
Vaccination against RSV and COVID-19 offers a critical strategy for mitigating the burden of respiratory diseases, particularly in vulnerable populations.
Beyond rescue inhalers: What really keeps COPD patients out of hospital?
Preventing hospital admissions for COPD requires a comprehensive approach, moving beyond acute symptom management to address the underlying disease progression and comorbidities.
Respiratory care: Why neurology's long-acting therapies could be key
Insights from multiple sclerosis treatment paradigms offer a framework for developing ultra-long-acting therapies in respiratory care, addressing adherence and disease progression.
COPD exercise limits: Is your oxygen therapy doing enough?
High-flow humidified oxygen improved exercise endurance and reduced dyspnea in patients with advanced COPD compared to conventional low-flow oxygen.
Air pollution: Why policies fail, and patients pay the price
Despite clear evidence linking air pollution to adverse health outcomes, effective implementation of protective policies remains a significant hurdle.
Obesity hypoventilation: CPAP vs. NIV, the economic tension
Obesity hypoventilation syndrome (OHS) can be managed with either CPAP or NIV, with device choice impacting economics and operations.
Beyond the numbers: What your PFT results are really telling you
Pulmonary function tests require an approach beyond simple normal/abnormal classifications, integrating clinical context and patient demographics for accurate diagnosis.
Rhinitis isn't just a nuisance: It's a key to managing asthma and COPD
Chronic inflammatory diseases of the upper and lower airways are often comorbid, sharing underlying pathophysiological mechanisms. Integrated management is essential for optimal patient outcomes.
Airway mucus: Is it a symptom or the disease driver in lung conditions?
Airway mucus obstruction is a central feature of many chronic lung diseases, contributing to inflammation, infection, and progressive lung damage.
Pulmonary fibrosis: Why early diagnosis remains a clinical enigma
Pulmonary fibrosis presents significant diagnostic and treatment challenges, often leading to delayed intervention and poorer outcomes for patients.
Bronchiectasis: Why symptom control isn't enough anymore
Bronchiectasis management is evolving beyond symptomatic relief, with a focus on neutrophil-driven inflammation as a target for disease modification.
NIV adherence: Why patient engagement is the real determinant of outcomes
Engaging patients actively in their non-invasive ventilation (NIV) therapy improves adherence and clinical outcomes. Education, shared decision-making, and tailored support are critical for success.
Chronic respiratory disease: Why diagnosis often comes too late
Understanding the patient journey for chronic respiratory diseases in resource-limited settings reveals significant diagnostic and treatment delays, impacting long-term outcomes.
Asthma care: Your patients need more than symptom relief
Current asthma management focuses on symptom control and exacerbation reduction, but patient-reported outcomes highlight persistent unmet needs.
High-flow oxygen: The unexpected boost for COPD endurance?
High-flow humidified oxygen improved exercise endurance and reduced dyspnea in patients with advanced COPD compared to conventional low-flow oxygen.
OPEP therapy: Is your current mucus clearance falling short?
Oscillating positive expiratory pressure (OPEP) therapy offers a non-pharmacological approach to mucus clearance across various respiratory conditions.
OSA: Why AHI alone isn't predicting your patients' heart risk
The apnea-hypopnea index (AHI) remains the standard for obstructive sleep apnea diagnosis, but its limitations in predicting cardiovascular outcomes are clear.
Why targeting IL-33 could change how we manage COPD
Interleukin-33 plays a complex role in COPD pathogenesis, driving both inflammation and mucus production, which contributes to exacerbation risk.
Severe asthma: Why biologics aren't delivering remission
Severe asthma remission is rare, even with biologic treatments, according to a European registry study highlighting persistent disease burden.
NTM lung disease: Why are we still missing it?
Non-tuberculous mycobacterial lung disease presents significant diagnostic and therapeutic challenges, often leading to delayed intervention and suboptimal patient outcomes.
Sleep Apnea: Why AHI Misses What Matters Most
Traditional AHI metrics often miss the full impact of sleep apnea; hypoxic burden and specific phenotyping offer a clearer picture of patient risk and device efficacy.
COPD: Why one moderate exacerbation changes everything
One moderate COPD exacerbation should prompt clinicians to consider stepping up from dual bronchodilator therapy to a single-inhaler triple therapy.
Chronic lung disease: Why early diagnosis still isn't enough
Managing chronic lung diseases presents complex challenges, from accurate diagnosis to optimising long-term treatment strategies and addressing patient adherence.
COPD: Why focusing only on exacerbations misses the bigger picture?
COPD management extends beyond preventing exacerbations, encompassing symptom burden, exercise capacity, and quality of life for a holistic patient approach.
COPD exacerbations: Why RSV's hidden role demands a new vaccine strategy
RSV infection significantly destabilizes COPD, driving exacerbations and hospitalizations. The adjuvanted RSV vaccine offers a new tool to mitigate this risk.
Epithelial health: more than a symptom of chronic inflammation?
Maintaining epithelial barrier integrity is emerging as a critical factor in achieving disease remission, moving beyond traditional symptom management in chronic inflammatory conditions.
Severe asthma, COPD: Why symptom control isn't enough
Managing severe asthma and COPD requires timely intervention, moving beyond symptomatic relief to address underlying inflammation and prevent exacerbations.
Ventilation: Why static guidelines fail dynamic patients
Continuous-improvement ventilation relies on real-world data to refine protocols and enhance patient outcomes, moving beyond static guidelines.
COPD: Why dual bronchodilation still isn't working for some patients
Dual bronchodilation remains a cornerstone in COPD management, focusing on symptom control and exacerbation reduction.
Pneumococcal disease: Your patients need updated protection now
Pneumococcal disease remains a significant global health burden, with new GBD 2023 data highlighting persistent mortality in vulnerable populations.
COPD: Early aggressive therapy isn't just for lungs
Delayed optimisation of COPD management leads to significant adverse cardiopulmonary outcomes, underscoring the need for earlier, aggressive therapeutic strategies.
Personalized COPD care: Is your current approach missing the mark?
New approaches to chronic obstructive pulmonary disease (COPD) management focus on phenotype-guided therapies and early intervention strategies.
Alpha-1 Antitrypsin Deficiency: Beyond augmentation, a new path
Advancements in Alpha-1 Antitrypsin Deficiency (AATD) therapies focus on restoring functional AAT levels and achieving clinically meaningful endpoints beyond simple protein augmentation.
Eosinophil depletion: Why 'good enough' isn't enough anymore
Near-complete depletion of eosinophils is critical for optimal outcomes in eosinophil-driven diseases, moving beyond simple reduction to target the underlying pathogenic mechanism.
Pulmonary fibrosis: Is inflammation friend or foe?
Fibrotic interstitial lung diseases involve intertwined inflammation and fibrosis, with varying contributions that demand personalized treatment approaches.
Severe asthma, CRSwNP: Why targeting TSLP upstream changes everything
Thymic stromal lymphopoietin (TSLP) inhibition offers a novel strategy for epithelial-driven inflammatory diseases like severe asthma and chronic rhinosinusitis with nasal polyps.
Bronchoscopy training: Why 'hundreds of procedures' may no longer be enough
AI integration into flexible bronchoscopy training aims to improve procedural proficiency and diagnostic accuracy for respiratory specialists.
Pulmonary Hypertension: Your objective measures aren't telling the whole story
Patient-reported outcomes are essential for understanding the true burden of pulmonary arterial hypertension and guiding treatment decisions.
Long-term oxygen therapy: Are we missing the patient experience?
A new questionnaire, QuOTE, offers a simple, patient-reported method to evaluate the impact of long-term oxygen therapy on daily life. This tool provides a direct measure of patient experience, which has been historically difficult to quantify.
Respiratory inhalers: The hidden climate cost of patient care?
Addressing the environmental impact of respiratory care, particularly inhaler use, is becoming a critical consideration for clinical practice.
Asthma: Why are we still guessing when omics can personalize care?
New reviews highlight how omics technologies and artificial intelligence are transforming asthma diagnosis, prognosis, and treatment decisions, moving beyond empirical approaches.
IPF, PPF: Why patient and clinician views on disease impact diverge
Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis present unique challenges, with patient and pulmonologist perspectives often misaligned on disease impact and management.
Pulmonary hypertension: Are we missing a key driver of vascular remodeling?
The insulin-like growth factor (IGF) family contributes to vascular remodeling and endothelial dysfunction in PAH, suggesting potential as diagnostic biomarkers and therapeutic targets.
Pulmonary alveolar proteinosis: It's not surfactant overproduction
Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired GM-CSF signaling, leading to surfactant accumulation. Management focuses on whole lung lavage, but targeted therapies are emerging.
Rethinking COPD: Dupilumab shows type 2 inflammation matters
Dupilumab has demonstrated efficacy in both asthma and COPD, offering a new therapeutic avenue for patients with underlying type 2 inflammation.
Stop missing ILD: AI reveals what the eye can't see
Integrating artificial intelligence with clinical expertise can accelerate the identification of interstitial lung disease, potentially improving patient outcomes.
Rethinking asthma control: Why 'stable' isn't always enough
Achieving rapid and sustained control of asthma symptoms is critical for preventing exacerbations and improving long-term patient outcomes.
Why CPAP success isn't about the device, but the patient experience
Optimising CPAP therapy requires a shift from device-centric views to patient-centred care, addressing comfort, education, and ongoing support.
Why treating asthma and CRSwNP separately may fail your patients
Anosmia, or loss of smell, may serve as a crucial indicator of shared inflammatory pathways between asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), suggesting a unified airway disease. Its presence signals a systemic type 2 inflammatory burden that impacts treatment decisions and patient quality of life.
Pulmonary Hypertension: Why are we still going systemic?
Inhaled therapies are increasingly central to managing pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, offering targeted delivery and reduced systemic side effects.
COPD: Why are we still missing early diagnoses?
Chronic obstructive pulmonary disease often goes undiagnosed until advanced stages, delaying interventions that could improve patient outcomes. Identifying at-risk individuals earlier is critical for effective management.
Asthma, COPD: Why the 'right' drug often fails in the 'wrong' device
Matching the right inhaler device to a patient's needs remains a persistent challenge in respiratory care, despite a wide array of available options.
Rethinking PCV: Not all conjugate vaccines are equal for chronic lung disease
Real-world evidence on pneumococcal conjugate vaccines (PCVs) highlights differential effectiveness in adults with chronic lung disease.
Pulmonary alveolar proteinosis: Your patients deserve better
Pulmonary alveolar proteinosis (PAP) management across Europe faces significant disparities, driven by varied access to diagnostic tools and treatment modalities. A unified approach is critical for improving patient outcomes.
COPD & asthma: Why symptom control isn't enough anymore
Current management of COPD and asthma focuses on symptom control, but emerging strategies aim to alter disease progression itself.
Central sleep apnea: Why aren't we using ASV more?
Auto-servo ventilation (ASV) therapy is a guideline-recommended treatment for central sleep apnea (CSA), but its adoption in clinical practice remains inconsistent. Understanding ASV's mechanism and patient selection is important for optimal outcomes.
Alpha-1 Antitrypsin Deficiency: Why fragmented care costs lives
Alpha-1 antitrypsin deficiency presents as both a respiratory and hepatic disease, often leading to diagnostic delays and suboptimal management due to fragmented care.
Severe asthma: Why targeted therapies miss some Type 2 patients
Emerging clinical insights suggest the distal airways play a more central role in Type 2 severe asthma pathophysiology than previously understood.
PH-ILD: Why current vasodilators fall short, and what's next
An inhaled sGC activator is under investigation for pulmonary hypertension associated with interstitial lung disease, a condition with significant unmet need.
Beyond diagnosis: ECG waveforms predict MI-E treatment response
Electrocardiogram waveforms offer insights into myocardial infarction with epicardial coronary artery disease (MI-E) efficacy, providing a non-invasive window into myocardial health.
Rethink PDE inhibition in COPD: Not all isoforms are equal
Phosphodiesterase (PDE) inhibitors offer therapeutic potential in COPD, but adverse effects, particularly nausea with PDE4 inhibitors and cardiovascular risks with chronic PDE3 inhibition, limit their broader application.
IPF: Why new therapies are still missing the mark
The TETON Phase 3 clinical program provides new insights into the management of idiopathic pulmonary fibrosis, highlighting both progress and persistent challenges.
RSV and COVID-19 vaccines: Why are we still underestimating their impact?
Vaccination against RSV and COVID-19 offers a critical strategy for mitigating the burden of respiratory diseases, particularly in vulnerable populations.
Beyond rescue inhalers: What really keeps COPD patients out of hospital?
Preventing hospital admissions for COPD requires a comprehensive approach, moving beyond acute symptom management to address the underlying disease progression and comorbidities.
Respiratory care: Why neurology's long-acting therapies could be key
Insights from multiple sclerosis treatment paradigms offer a framework for developing ultra-long-acting therapies in respiratory care, addressing adherence and disease progression.
COPD exercise limits: Is your oxygen therapy doing enough?
High-flow humidified oxygen improved exercise endurance and reduced dyspnea in patients with advanced COPD compared to conventional low-flow oxygen.
Air pollution: Why policies fail, and patients pay the price
Despite clear evidence linking air pollution to adverse health outcomes, effective implementation of protective policies remains a significant hurdle.
Obesity hypoventilation: CPAP vs. NIV, the economic tension
Obesity hypoventilation syndrome (OHS) can be managed with either CPAP or NIV, with device choice impacting economics and operations.
Beyond the numbers: What your PFT results are really telling you
Pulmonary function tests require an approach beyond simple normal/abnormal classifications, integrating clinical context and patient demographics for accurate diagnosis.
Rhinitis isn't just a nuisance: It's a key to managing asthma and COPD
Chronic inflammatory diseases of the upper and lower airways are often comorbid, sharing underlying pathophysiological mechanisms. Integrated management is essential for optimal patient outcomes.
Airway mucus: Is it a symptom or the disease driver in lung conditions?
Airway mucus obstruction is a central feature of many chronic lung diseases, contributing to inflammation, infection, and progressive lung damage.
Pulmonary fibrosis: Why early diagnosis remains a clinical enigma
Pulmonary fibrosis presents significant diagnostic and treatment challenges, often leading to delayed intervention and poorer outcomes for patients.
Bronchiectasis: Why symptom control isn't enough anymore
Bronchiectasis management is evolving beyond symptomatic relief, with a focus on neutrophil-driven inflammation as a target for disease modification.
NIV adherence: Why patient engagement is the real determinant of outcomes
Engaging patients actively in their non-invasive ventilation (NIV) therapy improves adherence and clinical outcomes. Education, shared decision-making, and tailored support are critical for success.
Chronic respiratory disease: Why diagnosis often comes too late
Understanding the patient journey for chronic respiratory diseases in resource-limited settings reveals significant diagnostic and treatment delays, impacting long-term outcomes.
Asthma care: Your patients need more than symptom relief
Current asthma management focuses on symptom control and exacerbation reduction, but patient-reported outcomes highlight persistent unmet needs.
High-flow oxygen: The unexpected boost for COPD endurance?
High-flow humidified oxygen improved exercise endurance and reduced dyspnea in patients with advanced COPD compared to conventional low-flow oxygen.
OPEP therapy: Is your current mucus clearance falling short?
Oscillating positive expiratory pressure (OPEP) therapy offers a non-pharmacological approach to mucus clearance across various respiratory conditions.
OSA: Why AHI alone isn't predicting your patients' heart risk
The apnea-hypopnea index (AHI) remains the standard for obstructive sleep apnea diagnosis, but its limitations in predicting cardiovascular outcomes are clear.
Why targeting IL-33 could change how we manage COPD
Interleukin-33 plays a complex role in COPD pathogenesis, driving both inflammation and mucus production, which contributes to exacerbation risk.
Severe asthma: Why biologics aren't delivering remission
Severe asthma remission is rare, even with biologic treatments, according to a European registry study highlighting persistent disease burden.
NTM lung disease: Why are we still missing it?
Non-tuberculous mycobacterial lung disease presents significant diagnostic and therapeutic challenges, often leading to delayed intervention and suboptimal patient outcomes.
Sleep Apnea: Why AHI Misses What Matters Most
Traditional AHI metrics often miss the full impact of sleep apnea; hypoxic burden and specific phenotyping offer a clearer picture of patient risk and device efficacy.
COPD: Why one moderate exacerbation changes everything
One moderate COPD exacerbation should prompt clinicians to consider stepping up from dual bronchodilator therapy to a single-inhaler triple therapy.
Chronic lung disease: Why early diagnosis still isn't enough
Managing chronic lung diseases presents complex challenges, from accurate diagnosis to optimising long-term treatment strategies and addressing patient adherence.
COPD: Why focusing only on exacerbations misses the bigger picture?
COPD management extends beyond preventing exacerbations, encompassing symptom burden, exercise capacity, and quality of life for a holistic patient approach.
COPD exacerbations: Why RSV's hidden role demands a new vaccine strategy
RSV infection significantly destabilizes COPD, driving exacerbations and hospitalizations. The adjuvanted RSV vaccine offers a new tool to mitigate this risk.
Epithelial health: more than a symptom of chronic inflammation?
Maintaining epithelial barrier integrity is emerging as a critical factor in achieving disease remission, moving beyond traditional symptom management in chronic inflammatory conditions.
Severe asthma, COPD: Why symptom control isn't enough
Managing severe asthma and COPD requires timely intervention, moving beyond symptomatic relief to address underlying inflammation and prevent exacerbations.
Ventilation: Why static guidelines fail dynamic patients
Continuous-improvement ventilation relies on real-world data to refine protocols and enhance patient outcomes, moving beyond static guidelines.
COPD: Why dual bronchodilation still isn't working for some patients
Dual bronchodilation remains a cornerstone in COPD management, focusing on symptom control and exacerbation reduction.
Pneumococcal disease: Your patients need updated protection now
Pneumococcal disease remains a significant global health burden, with new GBD 2023 data highlighting persistent mortality in vulnerable populations.
COPD: Early aggressive therapy isn't just for lungs
Delayed optimisation of COPD management leads to significant adverse cardiopulmonary outcomes, underscoring the need for earlier, aggressive therapeutic strategies.
Personalized COPD care: Is your current approach missing the mark?
New approaches to chronic obstructive pulmonary disease (COPD) management focus on phenotype-guided therapies and early intervention strategies.
Alpha-1 Antitrypsin Deficiency: Beyond augmentation, a new path
Advancements in Alpha-1 Antitrypsin Deficiency (AATD) therapies focus on restoring functional AAT levels and achieving clinically meaningful endpoints beyond simple protein augmentation.
Eosinophil depletion: Why 'good enough' isn't enough anymore
Near-complete depletion of eosinophils is critical for optimal outcomes in eosinophil-driven diseases, moving beyond simple reduction to target the underlying pathogenic mechanism.
Pulmonary fibrosis: Is inflammation friend or foe?
Fibrotic interstitial lung diseases involve intertwined inflammation and fibrosis, with varying contributions that demand personalized treatment approaches.
Severe asthma, CRSwNP: Why targeting TSLP upstream changes everything
Thymic stromal lymphopoietin (TSLP) inhibition offers a novel strategy for epithelial-driven inflammatory diseases like severe asthma and chronic rhinosinusitis with nasal polyps.
Bronchoscopy training: Why 'hundreds of procedures' may no longer be enough
AI integration into flexible bronchoscopy training aims to improve procedural proficiency and diagnostic accuracy for respiratory specialists.
Pulmonary Hypertension: Your objective measures aren't telling the whole story
Patient-reported outcomes are essential for understanding the true burden of pulmonary arterial hypertension and guiding treatment decisions.
Long-term oxygen therapy: Are we missing the patient experience?
A new questionnaire, QuOTE, offers a simple, patient-reported method to evaluate the impact of long-term oxygen therapy on daily life. This tool provides a direct measure of patient experience, which has been historically difficult to quantify.
Respiratory inhalers: The hidden climate cost of patient care?
Addressing the environmental impact of respiratory care, particularly inhaler use, is becoming a critical consideration for clinical practice.
Asthma: Why are we still guessing when omics can personalize care?
New reviews highlight how omics technologies and artificial intelligence are transforming asthma diagnosis, prognosis, and treatment decisions, moving beyond empirical approaches.
IPF, PPF: Why patient and clinician views on disease impact diverge
Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis present unique challenges, with patient and pulmonologist perspectives often misaligned on disease impact and management.
Pulmonary hypertension: Are we missing a key driver of vascular remodeling?
The insulin-like growth factor (IGF) family contributes to vascular remodeling and endothelial dysfunction in PAH, suggesting potential as diagnostic biomarkers and therapeutic targets.
Pulmonary alveolar proteinosis: It's not surfactant overproduction
Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired GM-CSF signaling, leading to surfactant accumulation. Management focuses on whole lung lavage, but targeted therapies are emerging.
Rethinking COPD: Dupilumab shows type 2 inflammation matters
Dupilumab has demonstrated efficacy in both asthma and COPD, offering a new therapeutic avenue for patients with underlying type 2 inflammation.
Stop missing ILD: AI reveals what the eye can't see
Integrating artificial intelligence with clinical expertise can accelerate the identification of interstitial lung disease, potentially improving patient outcomes.
Rethinking asthma control: Why 'stable' isn't always enough
Achieving rapid and sustained control of asthma symptoms is critical for preventing exacerbations and improving long-term patient outcomes.
Why CPAP success isn't about the device, but the patient experience
Optimising CPAP therapy requires a shift from device-centric views to patient-centred care, addressing comfort, education, and ongoing support.
Why treating asthma and CRSwNP separately may fail your patients
Anosmia, or loss of smell, may serve as a crucial indicator of shared inflammatory pathways between asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), suggesting a unified airway disease. Its presence signals a systemic type 2 inflammatory burden that impacts treatment decisions and patient quality of life.
Pulmonary Hypertension: Why are we still going systemic?
Inhaled therapies are increasingly central to managing pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, offering targeted delivery and reduced systemic side effects.
COPD: Why are we still missing early diagnoses?
Chronic obstructive pulmonary disease often goes undiagnosed until advanced stages, delaying interventions that could improve patient outcomes. Identifying at-risk individuals earlier is critical for effective management.
Asthma, COPD: Why the 'right' drug often fails in the 'wrong' device
Matching the right inhaler device to a patient's needs remains a persistent challenge in respiratory care, despite a wide array of available options.
Rethinking PCV: Not all conjugate vaccines are equal for chronic lung disease
Real-world evidence on pneumococcal conjugate vaccines (PCVs) highlights differential effectiveness in adults with chronic lung disease.
Pulmonary alveolar proteinosis: Your patients deserve better
Pulmonary alveolar proteinosis (PAP) management across Europe faces significant disparities, driven by varied access to diagnostic tools and treatment modalities. A unified approach is critical for improving patient outcomes.
COPD & asthma: Why symptom control isn't enough anymore
Current management of COPD and asthma focuses on symptom control, but emerging strategies aim to alter disease progression itself.
Central sleep apnea: Why aren't we using ASV more?
Auto-servo ventilation (ASV) therapy is a guideline-recommended treatment for central sleep apnea (CSA), but its adoption in clinical practice remains inconsistent. Understanding ASV's mechanism and patient selection is important for optimal outcomes.
